ThromboGenics publishes phase III data of ocriplasmin for VMT

Friday, August 17, 2012 03:11 PM

ThromboGenics, a Belgium-based biopharmaceutical company focused on ophthalmic medicines, has published data from two phase III clinical trials evaluating ocriplasmin for the treatment of Vitreomacular Adhesion (VMA) and macular holes in the New England Journal of Medicine.

The paper highlights that a single intravitreal injection of ocriplasmin resolved VMA, releasing traction and closing macular holes in significantly more patients than placebo.

The two multinational, randomized, double-blind phase III trials enrolled 652 patients with VMA, a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. Both studies met the primary endpoint of pharmacological resolution of VMA at day 28. Secondary endpoints included nonsurgical closure of a macular hole at 28 days, avoidance of vitrectomy (surgery) and improvement in visual acuity.

The phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.001). Nonsurgical closure of macular holes occurred in 40.6% of ocriplasmin-treated patients, compared with 10.6% of patients on placebo (p<0.001). Patients given ocriplasmin were more likely to achieve a vision gain of at least three lines compared with placebo. Treatment with ocriplasmin was associated with some, mainly transient ocular adverse events.

"This New England Journal of Medicine paper highlights data showing ocriplasmin's potential to become the first pharmacological option for the treatment of symptomatic VMA and macular holes. An in-office injection would be a new and possibly earlier alternative treatment for the vitreoretinal surgeon to offer to patients with these sight threatening disorders. Ocriplasmin represents a potential new treatment paradigm for the retina community and for our patients with VMA and macular holes,” said Dr. Julia Haller, ophthalmologist-in-chief of the Wills Eye Institute.

ThromboGenics has made regulatory filings for ocriplasmin in both the U.S. and Europe. Last month, an FDA advisory panel recommended the approval of ocriplasmin for the treatment of symptomatic VMA. If approved, the company plans to commercialize ocriplasmin itself in the U.S. Ocriplasmin is also currently under regulatory review by the EMA. In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the U.S.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs